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Abstract
Background: Ovarian carcinoma is the leading cause of mortality among gynecological cancers in the world. The
high mortality rate is associated with lack of early diagnosis and development of drug resistance. The antitumor
efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied.
Methods: NCX-4040, alone or in combination with cisplatin (cis-diamminedichloroplatinum, cDDP), was studied
in cisplatin-sensitive (A2780 WT) and cisplatin-resistant (A2780 cDDP) cell lines as well as xenograft tumors
grown in nude mice. Electron paramagnetic resonance (EPR) was used for measurements of nitric oxide and
redox state. Immunoblotting analysis of A2780 cDDP tumor xenografts from mice was used for mechanistic
studies.
Results: Cells treated with NCX-4040 (25 μM) showed a significant reduction of cell viability (A2780 WT, 34.9
± 8.7%; A2780 cDDP, 41.7 ± 7.6%; p < 0.05). Further, NCX-4040 significantly enhanced the sensitivity of A2780
cDDP cells (cisplatin alone, 80.6 ± 11.8% versus NCX-4040+cisplatin, 26.4 ± 7.6%; p < 0.01) and xenograft tumors
(cisplatin alone, 74.0 ± 4.4% versus NCX-4040+cisplatin, 56.4 ± 7.8%; p < 0.05), to cisplatin treatment. EPR imaging
of tissue redox and thiol measurements showed a 5.5-fold reduction (p < 0.01) of glutathione in NCX-4040-
treated A2780 cDDP tumors when compared to untreated controls. Immunoblotting analysis of A2780 cDDP
tumor xenografts from mice treated with NCX-4040 and cisplatin revealed significant downregulation of pEGFR
(Tyr845 and Tyr992) and pSTAT3 (Tyr705 and Ser727) expression.
Conclusion: The results suggested that NCX-4040 could resensitize drug-resistant ovarian cancer cells to
cisplatin possibly by depletion of cellular thiols. Thus NCX-4040 appears to be a potential therapeutic agent for
the treatment of human ovarian carcinoma and cisplatin-resistant malignancies.
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Ovarian carcinoma is the leading cause of mortality
among gynecological cancers in the world. The high mor-
tality rate is attributed to the lack of early diagnosis of the
malignancy and difficulties associated with treatment.
Ovarian cancer is treated using cisplatin drugs; however,
relapse of the disease involving a substantial population
of cisplatin-resistant cells is commonly observed [1]. The
development of drug resistance is a major impediment
toward successful treatment of the recurrent cancer [2].
Substantially higher doses of cisplatin and paclitaxel are
required to treat the recurrent disease. However, at high
doses, these drugs have been known to cause undesirable
side effects. For example, cisplatin causes significant
nephro- [3], neuro- [4], and ototoxicity [5] while paclit-
axel is associated with neurotoxicity and neutropenia [6].
Thus, there have been a number of studies aimed at
understanding the causes of drug resistance, so as to
develop strategies to overcome or avoid this complication
[7-9]. To date, several mechanisms of cisplatin resistance
in ovarian cancer cells have been proposed, including
decreased cellular uptake and increased cellular efflux of
cisplatin [8], inactivation of intracellular cisplatin by glu-
tathione [10-12], and increased levels of DNA repair and
DNA tolerance [12,13].
In the past, there have been enormous efforts to develop
alternative drugs to treat the recurrent disease. Derivatives
of cisplatin, such as carboplatin, oxaliplatin, paclitaxel,
doxorubicin, and a variety of alkylating agents have been
studied as potential agents to eliminate the resistant cells
[1,2]. Also, several strategies were explored to resensitize
the refractory cells to established modes of treatment
without undesirable side effects. Depletion of cellular
thiol levels in the drug-resistant cancer cells is one of the
more promising strategies that has been shown to be sig-
nificantly effective in a number of cases [14-17].
Recently, we showed that NCX-4016, a nitro derivative of
aspirin, inhibited the proliferation of cisplatin-sensitive as
well as cisplatin-resistant human ovarian cancer cell lines
in vitro [18]. We also showed that NCX-4016, on incuba-
tion with the cisplatin-resistant cells, generated sustained
levels of nitric oxide (NO) and substantially depleted cel-
lular thiols. In a subsequent report, we further showed
that NCX-4016, by itself, was capable of inhibiting the
growth of cisplatin-resistant human xenograft tumors in
mice [19]. We determined that NCX-4016 induced G1
cell-cycle arrest and apoptosis by inhibiting the EGFR/
PI3K and STAT3 signaling pathways. Subsequent to the
initial reports on NCX-4016, there have been a few reports
on NCX-4040 (Figure 1A), a positional isomer of NCX-
4016 [20], that demonstrated significant cytotoxic effect
on pancreatic [21], bladder [22], and colon cancer [23-
25]. It was reported that NCX-4040 was 100 times more
potent than NCX-4016 in HT-29 human colon cancer
cells [26]. However, its cytotoxic effect on human ovarian
cancer has not been investigated. Therefore, the goal of
the present work was to study the antitumor efficacy and
potential of NCX-4040 to sensitize cisplatin-resistant
ovarian cancer cells to cisplatin treatment. The experi-
ments were performed using cisplatin-sensitive (A2780
WT) and cisplatin-resistant (A2780 cDDP) human ovar-
ian cancer cell lines and xenograft tumors. The results
showed that administration of NCX-4040 decreased cellu-
lar thiol levels, thereby sensitizing the drug-resistant cells
to cisplatin. NCX-4040, in combination with cisplatin,
inhibited tumor growth by downregulation of EGFR and
STAT3 signaling.
Comparision of the structure and effect of NCX-4040 and NCX-4016 on cell viabilityFigure 1
Comparision of the structure and effect of NCX-4040 
and NCX-4016 on cell viability. (A) Molecular structure 
of NCX-4040 (acetyloxy)benzoic acid 4-(nitrooxyme-
thyl)phenyl ester) and NCX-4016 (2-(acetyloxy)benzoic acid 
3-(nitrooxymethyl)phenyl ester). The nitroaspirins consist of 
acetylsalicylate (aspirin) linked to a spacer moiety by an ester 
bond. An NO-releasing moiety (-ONO2) is attached to the 
spacer. (B) Effect of NCX-4040 and NCX-4016 (25 μM) on 
the viability of cisplatin-resistant human ovarian cancer cells 
(A2780 cDDP). The results show a dose-dependent cyto-
toxic effect, with NCX-4040 demonstrating a substantially 
higher effect compared to NCX-4016.Page 2 of 12
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Reagents
NCX-4040 (2-(acetyloxy)benzoic acid 4-(nitrooxyme-
thyl) phenyl ester) was obtained from NicOx (Sophia
Antipolis, France). GSH (L-glutamyl-L-cysteinylglycine),
aspirin (ASA), dimethylsulfoxide (DMSO), buthionine
sulfoximine (BSO), S-Nitroso-N-acetylpenicilamine
(SNAP), MTT powder (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) were obtained from
Sigma. 4-amino-5-methylamino-2', 7'-difluorofluores-
cein diacetate (DAF-FM DA was obtained from Molecular
Probes. Cisplatin (cis-diamminedichloroplatinum),
ammonium iron(II) sulfate hexahydrate, and acetonitrile
were purchased from Aldrich. Cell culture medium (RPMI
medium 1640), fetal bovine serum (FBS), antibiotics,
sodium pyruvate, trypsin, and phosphate-buffered saline
(PBS) were purchased from GIBCO/BRL. The imidazoline
biradical probes R1S-SR1 (bis(2,2,5,5-tetramethyl-3-imi-
dazoline-1-oxyl-4-il)disulfide) and R2S-SR2
(bis((2,2,3,5,5-pentamethyl-1-oxyl-imidazolidinyl-4)-
methyl)-disulfide) were synthesized as previously
reported [27]. N-methyl-D-glucaminedithiocarbamate
(MGD) was synthesized and purified in our laboratory
[28]. Polyvinylidene fluoride (PVDF) membrane and
molecular weight markers were obtained from Bio-Rad
(Hercules, CA). Antibodies for pEGFR (Tyr845, Tyr992),
EGFR, pSTAT3 (Tyr705 and Ser727), poly-adenosine
diphosphate ribose polymerase (PARP), cleaved caspases-
3, Bcl-xL, and Bax were purchased from Cell Signaling
Technology (Beverly, MA). Antibodies for p53, Survivin,
CycD1, and STAT3 were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Enhanced chemilumines-
cence (ECL) reagents were obtained from Amersham
Pharmacia Biotech (Buckinghamshire, UK).
Ovarian cancer cell lines
Cisplatin-sensitive (A2780 WT) and cisplatin-resistant
(A2780 cDDP) human ovarian cancer cell lines were used.
The cisplatin-resistant cell line was originally developed
from an in vivo tumor model by treating with cisplatin
[29]. Cells were grown in RPMI medium 1640 supple-
mented with 10% FBS, 2% sodium pyruvate, and 1% pen-
icillin/streptomycin. Culture and drug-treatment of cells
were carried out at 37°C in an atmosphere of 95% air/5%
CO2. Cells were routinely trypsinized (0.05% trypsin/
EDTA) and counted using an automated counter (Nucle-
oCounter, New Brunswick Scientific Co., Edison, NJ).
Cell viability assay
Cytotoxicity of the compounds was determined using the
conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to formazan via mito-
chondrial oxidation. Cells were grown in 75-cm2 flasks to
70% confluence, trypsinized, counted, and plated at a
density of 20,000 cells per well in 96 well plates. Cells
were incubated overnight and then treated with NCX-
4040, ASA and/or cisplatin at variable concentrations for
designated lengths of time. All experiments were repeated
at least three times. NCX-4040 was dissolved in dimethyl
sulfoxide (DMSO) and added into the culture. The final
DMSO concentration never exceeded 1%, and this condi-
tion was used as the control in each experiment. Cisplatin
was dissolved in DMSO (16 mg/ml) and stored at -20°C.
The stock solution was diluted to the final concentration
prior to each treatment.
The synergism of NCX-4040 and cisplatin was calculated
as described [30]. An expected value of cell survival, Sexp,
was defined as the product of the survival observed for
NCX-4040 and the survival observed for cisplatin (cDDP):
Sexp = SNCX-4040*ScDDP. The actual survival observed for the
combination treatment was defined as Sobs. The synerges-
tic ratio, R, was calculated as: R = Sexp/Sobs. Synergy was
defined for R > 1.
Measurement of nitric oxide generation using EPR 
spectroscopy
Generation of NO from NCX-4040 by cells incubated
with the compound was measured by EPR spectroscopy
using Fe(MGD)2 spin trap. The spin trap reacts with NO
and forms a stable complex Fe(MGD)2-NO which can be
detected using EPR. A2780 WT and A2780 cDDP cells
were cultured in 75-cm2 flasks. When cells reached 70%
confluence, they were trypsinized and resuspended to a
final concentration of 20 million cells per milliliter. The
cell suspension was added with NCX-4040 (100 μM) and
Fe(II)(MGD)2, an NO spin-trap prepared in deoxygenated
PBS by mixing 1 mM Fe2+ with 5 mM MGD. The NO
measurements were performed using a Bruker ER300 X-
band EPR spectrometer. The EPR spectra were collected at
20-mW microwave power using the following settings:
modulation amplitude, 3 G; modulation frequency, 100
kHz; time constant, 8 ms; scan time, 21 s. SNAP was used
as a positive control for NO detection.
Confocal fluorescence microscopic imaging
Nitric oxide production in A2780 cDDP cells was ana-
lyzed using confocal fluorescence microscopic imaging.
DAF-FM DA (4-amino-5-methylamino-2',7'-difluorofluo-
rescein diacetate), a green fluorescence probe specific for
NO, was added (10 μM) to cells treated with NCX-4040
(100 μM; 0, 1, 2 and 4 h). The probe was diluted in serum
and phenol red-free culture medium. Cells were incu-
bated with DAF-FM DA for 30 min at 37°C and then for
15 min without probe to allow complete de-esterification
of the intracellular diacetate. Fluorescence measurements
were made using a Zeiss LSM 510 multiphoton confocal
microscope (excitation, 488 nm; emission, 515 nm).
Quantitative analysis of fluorescence intensity was per-
formed using MetaMorph Software.Page 3 of 12
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Female 6-week-old BALB/c nude mice were obtained from
the National Cancer Institute. The animals were housed
five per cage in a climate- and light-controlled room. Food
and water were allowed ad libitum. All animals were used
according to the Public Health Services Policy, the Federal
Welfare Act, and ILACUC procedures and guidelines. The
mice were anesthetized with ketamine (200 mg/kg b.w.)
and xylazine (4 mg/kg b.w.) by intraperitoneal (i.p.)
injection. The animals inhaled room room air (21% O2)
during the in vivo spectroscopy, as well as for imaging. The
body temperature of the animal was maintained at 37 ±
1°C by an infrared lamp placed just above the animal dur-
ing the measurements.
Ovarian cancer tumor xenografts in mice
Cisplatin-sensitive (A2780 WT) and cisplatin-resistant
(A2780 cDDP) human ovarian cancer cells (5 × 106 cells
in 60 μl of PBS) were injected subcutaneously (s.c.) into
the upper portion of the right hind limb of BALB/c nude
mice. Both types of cells grew, in vivo, as a solid tumor. The
size of the tumor was measured three times per week
using a Vernier caliper. The tumor volume was deter-
mined from the orthogonal dimensions (d1, d2, d3) using
the formula (d1*d2*d3)* π/6.
In vivo study of NCX-4040 efficiency and redox study
On the 7th day after inoculation, when the tumor size
reached approximately 3–5 mm, the mice were subjected
to the treatment regime. The mice received i.p. injections
of (1) 5 mg/kg b.w. of NCX-4040 alone, daily; (2) 5 mg/
kg b.w. of ASA alone, daily; (3) 8 mg/kg b.w. of cisplatin
on the 11th day alone; or (4) 5 mg/kg b.w. of NCX-4040
daily, followed by cisplatin treatment on the 11th day (8
mg/kg b.w.). The control group was administered with the
vehicle alone (5). At the end of experiment (25th day) the
mice were sacrificed. The tumor tissues were then resected
and stored in liquid nitrogen up to the time of thiol level
determination and immunoblotting analysis.
Thiol (GSH) assay
Tissue levels of thiols were determined by X-band EPR
spectroscopy, using a thiol-specific imidazoline biradical
probe [31]. The probe reacts with reduced thiol and shows
a characteristic EPR spectrum, which can be quantified by
using known amounts of glutathione (GSH). One hun-
dred mg of thawed tissue were homogenized, in 2 ml of
PBS, using a tissue homogenizer (PCR Tissue Homogeniz-
ing Kit, Fisher Scientific) to obtain a uniform tissue sus-
pension. The tissue homogenate was treated with the
thiol-specific label R1S-SR1 (0.5 mM) at pH 7.0 for 7 min,
and the EPR spectra were measured. The concentration of
GSH was determined from a standard curve prepared with
known concentrations of GSH under similar conditions.
In vivo redox and imaging measurements
Tumor-bearing mice were intratumorally (i.t.) injected
with 15 μL of thiol-sensitive probe, R2S-SR2 [27]. Then
EPR measurements were taken immediately and every 1.5
min thereafter for a total of 30 min, during which the sig-
nal-decay was observed. The measurements were per-
formed using a home-built L-band (1.2 GHz) EPR
spectrometer with a bridged loop-gap resonator [32]. In
vivo EPR redox images were obtained on the 25th day of
tumor growth. Mice were intratumorally injected with 15
μL of R2S-SR2 [27]. The probe upon reaction with thiols is
converted to nitroxide. The total redox information can be
obtained from the decay of the nitroxide EPR signal,
which depends primary upon reduction factors in the tis-
sue. Mapping of the EPR probe location and its decay was
obtained by spatial EPR imaging (EPRI) methods that are
well established in our laboratory [32,33]. The EPRI meas-
urements were performed by using a home-built L-band
(1.2 GHz) EPR spectrometer with a bridged loop-gap res-
onator [32].
Immunoblot analysis
The tumor tissues were homogenized in a lysis buffer con-
taining 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Tri-
ton X-100, 1 mM EDTA, 1 mM EGTA, 0.3 mM
phenylmethylsulfonyl fluoride (PMSF), 0.2 mM sodium
orthovanadate, 0.5% NP40, 1 μg/ml aprotinin, and 1 μg/
ml leupetin. The homogenate was clarified by centrifuga-
tion. The protein concentration in the lysates was deter-
mined using a Pierce detergent-compatible protein assay
kit (Rockford, IL). For immunoblotting, 50 to 100 μg of
tissue protein per sample was denatured in 2× SDS-PAGE
sample buffer (0.5 mM Tris HCl, 60% glycerol, 10% SDS,
and β-mercapto-ethanol, bromophenol blue) and sub-
jected to SDS-PAGE on a 10% or 12% tris-glycine gel. The
separated proteins were transferred onto a PVDF mem-
brane. The membrane was blocked with 5% nonfat milk
powder (w/v) in Tris-buffered saline Tween-20 (TBST; 10
mM Tris, 100 mM NaCl, 0.1% Tween 20) for 1 h at room
temperature or overnight at 4°C. The membranes were
incubated overnight with the respective primary antibod-
ies. The bound antibodies were detected with horseradish
peroxidase (HRP)-labeled sheep anti-mouse IgG or HRP-
labeled donkey anti-rabbit IgG (Amersham Pharmacia
Biotech) using an ECL detection system. The ECL image
was digitized using a scanner (ScanJet 7400c, Hewlett-
Packard, Palo Alto, CA) and quantified using densitome-
try software (Scion Image v0.4.0.2, Scion, Frederick, MD).
Statistical analysis
Data were expressed as mean ± SD (in vitro study) or mean
± SEM (in vivo study). Comparisons among groups were
performed by using a Student's t test. The significance
level was set at p < 0.05.Page 4 of 12
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NCX-4040 enhances cisplatin cytotoxicity in ovarian 
cancer cell lines
NCX-4040 is a positional isomer of NCX-4016 (Figure
1A), which we have previously reported to be cytotoxic to
human ovarian cancer cell lines [18]. In order to evaluate
the anticancer efficacy of NCX-4040 and to compare with
that of NCX-4016, we performed a dose-response study
using cisplatin-resistant cell line (A2780 cDDP). As seen
in Figure 1B, a dose-dependent decrease of cell viability
was observed in both cases. However, NCX-4040 showed
a substantial decrease in cell viability when compared to
NCX-4016. The cytotoxic effects of NCX-4040, either
alone or in combination with cisplatin, on A2780 WT and
A2780 cDDP cell lines were determined. Cells were
treated with NCX-4040 (25 μM) for 6 h followed by cispl-
atin (IC67 dose for A2780 WT cells) for 1 h with a 24-h fol-
low up time. Cytotoxicity was assessed using an MTT
viability assay. The results (Figure 2) showed that NCX-
4040 alone significantly decreased the viability of both
A2780 WT (34.9 ± 8.7%) and A2780 cDDP (41.7 ± 7.6%)
cell lines. Cisplatin (cDDP) alone significantly decreased
the viability of A2780 WT (31.5 ± 3.4%), but not A2780
cDDP (80.6 ± 11.8%) cell lines. On the other hand, com-
bination of cisplatin and NCX-4040 was more effective
than cisplatin or NCX-4040 alone in decreasing the viabil-
ity of both A2780 WT (9.4 ± 6.0%) and A2780 cDDP
(26.4 ± 7.6%) cell lines. A weak synergism was observed
(R = 1.27, see Methods for calculation) between NCX-
4040 and cisplatin in the killing of A2780 cDDP cells. The
results clearly demonstrated that NCX-4040 was not only
cytotoxic, but also capable of sensitizing cisplatin-resist-
ant ovarian cancer cells to cisplatin.
NCX-4040 generates NO in cells
To determine whether NCX-4040 can generate NO in
cells, we performed EPR spectroscopic measurements on
A2780 WT and A2780 cDDP cells incubated with 100 μM
of NCX-4040. Fe(MGD)2 was used as a spin-trap for real-
time detection of NO. Fe(MGD)2 reacts with NO and
forms a stable paramagnetic adduct, Fe(MGD)2-NO,
which can be detected by EPR spectroscopy [34]. NCX-
4040 or cells alone in media did not generate any signal
(Figure 3A). However, a prominent triplet signal with a
hyperfine coupling constant of 12.5 G, characteristic of
Fe(MGD)2-NO, was observed upon incubation of NCX-
4040 with the cells. The authenticity of the spectra was
verified using S-nitroso-N-acetylpenicillamine (SNAP,
100 μM), a known NO-releasing compound. Both cell
lines demonstrated a time-dependent increase in the
intensity of Fe(MGD)2-NO signal (Figure 3B) starting at
40–50 min of co-incubation time. While the rate of NO
generation was steady in the case of A2780 WT cells, a
rapid increase followed by slow attenuation was observed
in the case of A2780 cDDP cells. In order to determine
whether or not the increased rate of NO generation in
A2780 cDDP cells was due to thiols, we pre-incubated
A2780 cDDP cells with 1 mM buthionine sulfoximine
(BSO), an inhibitor of glutathione synthesis, for 24 h and
then treated with NCX-4040. As seen in Figure 3B, the NO
generation was significantly decreased upon BSO treat-
ment, suggesting that the NO generation was mediated by
cellular thiols. In contrast, NO generation by SNAP was
instant and lasted only for a few minutes (data not
shown). We further imaged the intracellular NO genera-
tion using DAF-FM DA (Figure 3C). These results shown
in Figure 3D clearly demonstrated a sustained generation
of NO by NCX-4040 in the cancer cells. Thus, the NO gen-
eration by NCX-4040 in cancer cells was low, but persisted
for longer periods.
NCX-4040 inhibits tumor growth in mice
The anti-tumor efficacy of NCX-4040 was studied using
A2780 cDDP tumor xenografts in mice. Tumor-bearing
animals, on day 7 post-inoculation, were treated with
Effect of NCX-4040 and/or cisplatin on the viability of A2780 WT and A2780 cDDP cell linesFigure 2
Effect of NCX-4040 and/or cisplatin on the viability of 
A2780 WT and A2780 cDDP cell lines. Cells were incu-
bated with 25 μM of NCX-4040 for 6 h, then with cisplatin 
for 1 h (IC67 dose for A2780 WT) with a 24 h follow up time. 
Cell viability was evaluated using MTT assay. Data represent 
mean ± SD obtained from 4 independent experiments and 
expressed as a percentage of the control cells treated with 
vehicle (1% DMSO). *p < 0.01 versus Control group. **p < 
0.05 versus cDDP or NCX-4040 group.Page 5 of 12
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section. The tumor volumes were measured every 2 days
for 19 days post-inoculation. As shown in Figure 4, NCX-
4040 treatment alone did not show any significant reduc-
tion in tumor volume (85.8 ± 9.8% versus Control on day
19; Figure 4B). Cisplatin (cDDP) treatment alone signifi-
cantly reduced the tumor growth volume (74.0 ± 4.4%
versus Control). However, animals treated with a combi-
nation of cisplatin and NCX-4040 showed a significant
reduction in tumor volume visible from second day after
cisplatin treatment and reached 56.4 ± 7.8% versus Con-
trol on day 19. Aspirin (ASA), a metabolic product of
NCX-4040, did not show any significant effect on tumor
growth volume (Figure 4B). The results clearly demon-
strated that NCX-4040, in combination with cisplatin,
was more effective than cisplatin alone in inhibiting the
growth of cisplatin-resistant ovarian cancer xenografts in
mice.
NCX-4040 depletes thiol levels in the tumor xenografts
Since cisplatin-resistance in ovarian cancer is associated
with excessive thiol levels, we next wanted to check
whether NCX-4040 treatment could modify cellular thiol
levels in the solid tumor, in vivo. We performed in vivo
redox imaging of tumor xenografts in mice treated with
NCX-4040. As we have reported previously, the in vivo
redox mapping using EPR imaging enables noninvasive
and real-time visualization of tumor redox status, which is
Generation of nitric oxide (NO) by NCX-4040 in A2780 WT and A2780 cDDP cellsFigure 3
Generation of nitric oxide (NO) by NCX-4040 in A2780 WT and A2780 cDDP cells. (A) Representative EPR spec-
tra obtained from control (NCX-4040, A2780 cDDP cells) and NCX-4040 treatment (100 μM for both A2780 WT and A2780 
cDDP) groups. The cells were incubated with NCX-4040 in the presence of spin trap (MGD)2Fe. Also shown is an EPR spec-
trum of an authentic complex of NO with Fe(MGD)2 obtained by adding SNAP (an NO donor) to spin trap. (B) Time-course of 
nitric oxide release by NCX-4040 in A2780 WT, A2780 cDDP, and A2780 cDDP cells treated with 1 mM buthionine sulfox-
imine (BSO) for 24 h. (C) Representative DAF-FM DA fluorescence images of untreated (control) and treated (1, 2 or 4 hours) 
with NCX-4040 (100 μM). (D) Quantitative results on the DAF-FM DA fluorescence data. *p < 0.01 versus Control group.Page 6 of 12
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reduced thiols, in the tissue [35]. We used a thiol-specific
di-nitroxyl redox probe R2S-SR2, which on reaction with
SH groups breaks down to a mono-nitroxyl with a charac-
teristic triplet EPR signal. The rate of conversion of di- to
mono-nitroxyl is a measure of thiol concentration in the
tumor. However, in solid tumors, the conversion is very
rapid due to excess concentration of thiols compared to
the probe. However, the subsequent slower reduction of
the EPR-active mono-nitroxyl to EPR-silent hydroxy-
lamine by the cellular reductants including thiols can be
monitored and used as a measure of tissue "redox" state.
Figure 5A shows typical time-course "redox" images
obtained after intra-tumoral injection of R2S-SR2 (100
mM, 15 μl) in the cisplatin-sensitive (A2780 WT) and cis-
platin-resistant (A2780 cDDP) ovarian xenograft tumors
treated with NCX-4040. The time-course images showed
In vivo redox images of ovarian xenograft tumors in miceFigure 5
In vivoredox images of ovarian xenograft tumors in 
mice. A redox-sensitive probe (R2SSR2) was injected intra-
tumorally (100 mM; 15 μl), then sequential images were 
obtained for 30 min. The EPR images show the probe distri-
bution in the tumor, while the tumor itself is not visible. (A) 
Representative images of time-course of redox probe distri-
bution in untreated A2780 WT and A2780 cDDP tumors, as 
well as in A2780 cDDP tumor treated with NCX-4040 (5 
mg/kg, daily). (B) Total in vivo redox levels expressed as a 
percent of A2780 WT level. (C) Glutathione (GSH) levels in 
the tumors excised on day 19 post-inoculation. Data repre-
sent mean ± SD obtained from 4 mice/group. *p < 0.05 versus 
A2780 WT group. **p < 0.05 versus A2780 cDDP group. The 
results demonstrate that NCX-4040 depleted thiol levels in 
the cisplatin-resistant tumor.
Effect of NCX-4040 and/or cisplatin (cDDP) on the growth volume of human ov rian cancer xenograft tumor in miceFigur 4
Effect of NCX-4040 and/or cisplatin (cDDP) on the 
growth volume of human ovarian cancer xenograft 
tumor in mice. Groups of mice (4–6 per group) were inoc-
ulated with the A2780 cDDP human ovarian cancer cells in 
the upper portion of hind leg. Seven days after inoculation, 
two groups were injected daily (i.p.) with NCX-4040 (5 mg/
kg), of which one group received a single i.p. injection of cis-
platin on day 11 (8 mg/kg). The third group received single 
dose of cisplatin on day 11 (8 mg/kg). One group received 
aspirin (5 mg/kg, daily). Control group received vehicle. (A) 
Tumor growth curve for control, cisplatin, and combination 
of treatment (NCX-4040 and cisplatin). (B) Tumor growth 
volume data (mean ± SE, expressed as percent of control 
group) on the 19th day after injection of cancer cells. *p < 
0.05 compared to control group. **p < 0.05 versus cDDP 
group. NCX-4040 and aspirin (ASA), a metabolic product of 
NCX-4040, showed no significant effect. The results show 
that pretreatment with NCX-4040 was effective in enhancing 
the efficacy of cisplatin in inhibiting the growth of cisplatin-
resistant ovarian cancer xenografts in mice.Page 7 of 12
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tin-resistant tumor as compared to that of the cisplatin-
sensitive tumor, presumably due to higher cellular reduct-
ants in the former cell type. Further, it was observed that
NCX-4040 treatment resulted in a substantial slow-down
of the redox decay, suggesting that the treatment might
have depleted the reductants in the cisplatin-resistant
tumor. Quantitative redox data from multiple experi-
ments (Figure 5B) showed that the total redox level was
significantly elevated in A2780 cDDP tumor, 182.1 ±
47.4% of A2780 WT tumors' redox. NCX-4040 treatment
significantly depressed the total redox level, to 33.3 ±
12.8% (5.5-fold decrease), in A2780 cDDP tumor. We
next wanted to measure the modulation of thiol-only lev-
els in the tumors. We performed GSH assay from excised
tumor tissues (in vitro) using EPR spectroscopy with
another thiol-specific probe R1SSR1, as described in Meth-
ods. As seen in Figure 5C, the GSH level was 179.5 ±
42.3% in A2780 cDDP tumor and it was depleted to 38.5
± 14.1% (a 4.7-fold decrease) after treatment with NCX-
4040. The results clearly showed that NCX-4040 depleted
thiol level in the cisplatin-resistant tumor.
NCX-4040 induces apoptosis by downregulating EGFR and 
STAT3 signaling
We recently observed that NCX-4016, an isomeric form of
NCX-4040, inhibited tumor growth by modulating EGFR/
PI3K and STAT3 signaling pathways [19]. Therefore, we
analyzed the EGFR and STAT3 proteins in the A2780
cDDP tumor xenografts from mice treated with NCX-
4040 and/or cisplatin. The immunoblots showed that the
expressions of pEGFR (Tyr845 and Tyr992) and pSTAT3
(Tyr705, Ser727) were clearly downregulated in the
tumors treated with NCX-4040 and cisplatin, when com-
pared to NCX-4040 or aspirin alone groups (Figure 6A).
The combination treatment also downregulated the cell-
Immunoblot analysis of tumor tissueFigure 6
Immunoblot analysis of tumor tissue. (A) Representative images of EGFR/PI3K and STAT3 signaling pathways. EGFR, 
pEGFR, pSTAT3, STAT3, cyclin D1, Bcl-xL, survivin, p53, actin; (B) images for Bax, cleaved caspase-3, and PARP proteins. (C) 
Analysis of cleaved caspase-3 protein band showing an increase of cleaved caspase-3 in cisplatin-resistant tumor treated with 
aspirin (ASA) or NCX-4040 (5 mg/kg, daily), and NCX-4040 (5 mg/kg, daily) with cisplatin (cDDP, 8 mg/kg, single dose). (D) 
Analysis of PARP protein band showing an increase of PARP in cisplatin-resistant tumor treated with aspirin (ASA), NCX-4040, 
and NCX-4040 with cisplatin (cDDP). *p < 0.05 versus untreated (Control) group.Page 8 of 12
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upregulated the p53 protein. The expression of the proap-
optotic protein Bax and apoptotic markers, including
cleaved caspase-3 and PARP, were upregulated in the co-
treatment group (Figure 6B–D). The results suggested that
administration of NCX-4040, in combination with cispla-
tin, inhibited tumor growth by inducing apoptosis
through downregulation of EGFR and STAT3 signaling in
the cisplatin-resistant ovarian cancer xenograft in mice.
Discussion
NCX-4040 belongs to a class of nitric oxide-releasing,
non-steroidal anti-inflammatory drugs (NO-NSAID) that
were originally developed to overcome the limitation of
classical NSAIDs [36]. The NCX-4040 molecule contains
an aspirin backbone attached to a -ONO2 moiety linked
via an aromatic molecular spacer. The -ONO2 group,
which is responsible for the release of NO, has been
shown previously to be required for its anticancer activity
[20-22,26]. NCX-4040 is related to NCX-4016 by a posi-
tional variation of the -ONO2 group; whereas the -ONO2
group is at the para position in NCX-4040, it is at meta
position in NCX-4016. The positional isomers, including
the ortho version (NCX-4060), have been shown to be
substantially different in their anticancer efficacies in HT-
29 human colon cancer and pancreatic cancer cell lines
[20,21,26]. The ortho- and para-isomers showed similar
IC50 values (1–5 μM) for cell-growth inhibition over 72 h,
whereas the IC50 of the meta-isomer was 200 to 500 μM. A
structure-activity study of the three isomers also revealed
that substituting an aliphatic for the aromatic spacer or
removing the -ONO2 group profoundly diminished their
ability to inhibit cell growth, whereas removal of the
acetyl group on the aspirin moiety did not affect cell
growth inhibition [20,21,26]. In addition, the three posi-
tional isomers exhibited substantial differences in their
metabolism and these differences correlated with their
differential effects on cancer cell growth, underscoring the
importance of positional isomerism in modulating drug
effects [20,21,26].
Cisplatin is a widely used chemotherapeutic agent against
a number of malignancies, including ovarian cancer [37].
However, development of drug-resistance following pro-
longed treatment or up on relapse of the disease is an
undesirable effect [1]. There is a huge volume of pub-
lished data that implicates intracellular glutathione as an
important factor in cisplatin resistance. Overexpression of
glutathione-S-transferase enzymes, which catalyze cou-
pling of glutathione to multiple reactive substrates, has
also been correlated with low response rate to cisplatin
therapy [38-40]. The glutathione-mediated cisplatin
resistance has been shown to occur through a number of
mechanisms including decreased cellular levels of cispla-
tin [8], inactivation of cisplatin by formation of glutath-
ione-cisplatin adduct [10-12], increased level of DNA
repair and DNA tolerance [12,13], and inhibition of some
of the mitochondrial alterations associated with apoptotic
commitment [41]. Our results demonstrated a 4.7-fold
depression of thiol levels in A2780 cDDP tumor up on
treatment with NCX-4040 (Figure 5). This, presumably,
was responsible for the resensitization of the tumor to cis-
platin, resulting in a significant reduction (56.4%) in
tumor volume (Figure 4). The mechanism by which NCX-
4040 depletes thiol, however, is not well understood. Gao
et al. showed the involvement of GSH and glutathione-S-
transferase in the biotransformation of NCX-4040 in the
cytosolic fraction of rat liver and colon tissues and in
intact HT-29 human colon cancer cells [20]. Other possi-
ble mechanisms of thiol depletion might include the
thiol-dependent metabolic conversion of the nitrate
group (-ONO2) to NO in cells and/or formation of nitro-
sothiols. For example, formation of S-nitrosoglutathione
(GSNO) from GSH and NO has been shown to result in a
dramatic decrease in GSH levels in activated neutrophils
[42]. GSNO itself has been shown to be involved in the
modulation of the activity of various enzymes including
glutathione-S-transferase [43] and glutathione reductase
[44], which is responsible for maintaining high intracellu-
lar concentrations of GSH. There is also a recent report
which shows that the reaction of other metabolites of
nitroaspirin with GSH responsible for thiol depletion
[45].
While the cytotoxic effect of NCX-4040 against cisplatin-
sensitive (A2780 WT) cells was comparable to that of cis-
platin under the conditions used, its effect was signifi-
cantly higher in the resistant (A2780 cDDP) cells (Figure
2). This indicates that the anticancer potential of NCX-
4040 is not inhibited, but in fact potentiated to some
extent, by the elevated thiol concentrations in the resistant
cells. The substantially higher cytotoxicity induced by the
co-administration of NCX-4040 and cisplatin seems to
suggest a possible synergistic effect, presumably due to
NCX-mediated thiol depletion (Figure 5). Overall, the
results demonstrated a dual role for NCX-4040 in the
inhibition of drug-resistant ovarian tumor growth by
inducing NO-mediated cytotoxicity and resensitizing the
refractory cells to cisplatin. Further work is necessary to
elucidate their synergistic behavior.
In a previous study, we showed that the cytotoxic effect of
NCX-4016 was due to its slow metabolism leading to NO
release in cells [18]. We also showed that treatment of cis-
platin-resistant ovarian cancer cells with NCX-4016
depleted intracellular thiol levels [18]. In the presentPage 9 of 12
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(time-course) NO in cells (Figure 3) and substantial
depletion of thiols, as well as total redox, in the tumor tis-
sue (Figure 5). The results clearly demonstrated a cause/
effect advantage of thiol utilization/depletion by NCX-
4040-mediated NO generation in the cisplatin-resistant
ovarian carcinoma. Thus, we have shown that the anti-
tumoral and cisplatin-sensitization activities of NCX-
4040 were closely linked to its capacity to release NO in
the ovarian cancer cells. This is particularly important in
the context of a recent report that formation of a quinone
methide intermediate from para- (NCX-4040) and ortho-
(NCX-4060) nitroaspirin seems to be responsible for bio-
logical activity of these compounds [45-47]. According to
this report, the ASA derivative generates the p-quinone
and o-quinone methides, which rapidly react with GSH
and activate the antioxidant responsive element (ARE)
and NAD(P)H-dependent quinone oxidoreductase
(NQO1), probably via reaction with thiol-rich sensor pro-
teins [47]. In general, the metabolism of the meta-form of
nitroaspirin (NCX-4016) was slower. NCX-4016 could
not form a quinone, but ARE activation and NQO1 induc-
tion were observed with slower reaction with thiol-reach
proteins [47].
Epidermal growth factor receptor (EGFR) is over-
expressed in a wide variety of epithelial malignancies
including non-small cell lung, head and neck, colon, and
breast cancers [48]. Over-expression and increased activity
of EGFR are key characteristics of human tumors and are
frequently linked to more aggressive tumor behaviors,
including increased proliferation, metastasis, and thera-
peutic resistance [49]. As such, EGFR is considered to be a
key therapeutic target for human cancers [50]. Recent
studies have shown that activation of EGFR and STAT3
(signal transducers and activators of transcription 3) con-
fers resistance to chemotherapy-induced apoptosis in epi-
thelial malignancies [49,51]. STAT3 can be activated by
various protein tyrosine kinases including Janus tyrosine
kinases (JAK) and the proto-oncogene tyrosine kinase
(Src), as well as membrane-bound growth factor receptor
tyrosine kinases such as EGFR [52]. Many synthetic com-
pounds that inhibit phosphorylated STAT3 and EGFR
tyrosine kinase activity have been shown to be effective in
preclinical studies and in clinical trials of advance stages
of non-small cell lung cancer, breast, and ovarian cancer
[53-55]. However, a direct and consistent link between
the EGFR and iNOS/NO pathways has not been estab-
lished. For example, while EGF was shown to induce
iNOS expression in normal astrocytes and head and neck
squamous cell carcinomas [56], such a regulation was not
found in other cell systems. In ovarian carcinoma cells,
both exogenously applied NO and endogenously synthe-
sized NO have been shown to inhibit tumor growth [57].
Recently, we have shown that NCX-4016 suppressed the
growth of cisplatin-resistant human ovarian xenograft
tumor (A2780 cDDP) in mice by inducing G1 cell-cycle
arrest and apoptosis though inhibition of EGFR/PI3K and
STAT3 signaling pathways [19]. In the present study, we
also observed that treatment with NCX-4040 led to down-
regulation of EGFR and STAT3 levels. The blockage of
EGFR and STAT3-signaling cascades seemingly increased
the levels of p53, Bax and decreased levels of Bcl-xL, sur-
vivin, and cyclin D1 proteins. This, in turn, inhibited cel-
lular proliferation, and induced apoptosis in cisplatin-
resistant tumors. STAT3 is constitutively activated in a
variety of tumor cell types including A2780 cDDP ovarian
cancer cells [58]. The constitutively active STAT3 has been
implicated in the induction of resistance to apoptosis,
possibly through the expression of survivin, Bcl-2 and Bcl-
xL [55]. Bcl-xL, which is regulated by both STAT3 Tyr705
and Ser727, is known to be overexpressed in cells resistant
to chemotherapy [51,58]. It has been shown that blockage
of EGFR and STAT3 cascades resulted in the inhibition of
cancer cell proliferation and growth of prostate and liver
cancer via cell cycle arrest and apoptosis [50,53].
Conclusion
The present study demonstrated that NCX-4040 is not
only cytotoxic to human ovarian cancer cells, but is also
capable of resensitizing drug-resistant, recurrent tumors
to cisplatin treatment. NCX-4040 is capable of releasing
nitric oxide and depleting thiols in human ovarian cancer
cells. NCX-4040 can resensitize and potentiate the anti-
cancer effect of cisplatin through downregulation of EGFR
and STAT3 signaling in cisplatin-resistant human ovarian
tumor xenografts in mice. Thus, NCX-4040 appears to be
a potential therapeutic agent for the treatment of human
ovarian carcinoma.
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